MonoGen, Inc.

MonoGen, Inc.

November 05, 2007 08:00 ET

MonoGen Announces Addition of Jan L. Zorn as Vice President of Regulatory and Clinical Affairs

CHICAGO, ILLINOIS--(Marketwire - Nov. 5, 2007) - MonoGen, Inc. (TSX:MOG) ("Corporation") announced today the addition of Jan L. Zorn to its executive management team.

Ms. Zorn will join the company as Vice President of Regulatory and Clinical Affairs effective December 1, 2007. Jan has 34 years of experience with 25 of that specifically in the regulatory and clinical affairs area. Jan's recent history includes 4 years in the position of Vice President of Regulatory, Clinical and Quality Assurance at Optobionics Corporation as well as 5 years in the position of Director of Regulatory and Clinical Affairs at Aksys Ltd. Prior to that she held various regulatory and clinical affairs positions at Caremark, Baxter, and Amersham. She has conducted many multi-center clinical trials, generated FDA submissions, and received approvals for a number of Class 2 and Class 3 products. Ms. Zorn earned her BS in Biology from St. Mary's College in Notre Dame, Indiana.

"Jan's addition to our management team continues to validate MonoGen's commitment to attracting excellent talent to the corporation as we grow", commented Ted S. Geiselman, MonoGen's President and CEO. "Her experience is perfectly suited for the exciting and challenging clinical and regulatory roads ahead. She will be instrumental in helping to guide us in our quest to oversee studies that generate published data as well as FDA submissions that will expand our labeling claims in the future. I also would like to thank Gary Gamerman for his contributions to the company over the past five years. Gary has agreed to support MonoGen in the future during a transition period."

"I am very pleased to be joining MonoGen", affirmed Jan Zorn. "I look forward to working with the fine team Ted has recruited, and to helping make the exciting technology developed by the company available to the medical community."

Gary Gamerman added, "I am thrilled to be able turn RA/CA leadership over to Jan. As a shareholder, and after dedicating the past five years to MonoPrep's FDA approval, I am confident that her experience and track record will continue and extend MonoGen's regulatory successes. I look forward to helping her with the transition and being able to spend more time with my family."

Forward-Looking Statements

This press release contains statements that are forward-looking in nature. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements. Forward-looking statements are based on the Corporation's beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to the Corporation. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause the Corporation's actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to MonoGen's ability to raise additional capital, MonoGen's ability to execute its business plan while obtaining and maintaining at all times its various regulatory approvals, the performance of its strategic partners in the commercialization of the Corporation's products in the marketplace and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and the Corporation undertakes no obligation to update publicly or revise any forward looking information, whether as a result of new information, future events or otherwise.

Contact Information